Marie Louise (Marieke) De Bruin

PhD, PharmD

20002019

Research activity per year

Network

Hubert G M Leufkens

  • Utrecht University
  • Institute for Pharmaceutical Sciences UU

External person

Frank de Vries

  • Maastricht University
  • Utrecht University
  • Southampton General Hospital

External person

Arno W Hoes

  • Utrecht University

External person

Marloes T Bazelier

  • Utrecht University

External person

Flora E van Leeuwen

  • Antoni Van Leeuwenhoek Hospital
  • Netherlands Cancer Institute
  • Department of Epidemiology and Biostatistics

External person

Anthonius de Boer

  • Utrecht University

External person

Olaf H Klungel

  • Utrecht University

External person

Helga Gardarsdottir

  • Utrecht University

External person

Berthe M. P. Aleman

  • Netherlands Cancer Institute

External person

Jarno Hoekman

  • Utrecht University

External person

Sven Schmiedl

  • Witten University

External person

Marietta Rottenkolber

  • Ludwig Maximilian University of Munich

External person

Niels S Vermeer

  • Utrecht University

External person

Patrick C Souverein

  • Utrecht University

External person

Frans H Rutten

  • Utrecht University

External person

Toine C G Egberts

  • Utrecht University

External person

Marjanka K Schmidt

  • Netherlands Cancer Institute

External person

Consuelo Huerta

  • Division of Pharmacoepidemiology and Pharmacovigilance

External person

Mark C H de Groot

  • Utrecht University

External person

Tjeerd P. van Staa

  • Clinical Practice Research Datalink
  • Utrecht University
  • Manchester Business School, University of Manchester, Manchester

External person

Jim Slattery

  • European Medicines Agency
  • European Medicines Agency

External person

Paul J H L Peeters

  • Utrecht University

External person

Nicola S Russell

  • Antoni Van Leeuwenhoek Hospital
  • Netherlands Cancer Institute

External person

Jacoline C Bouvy

  • Utrecht University
  • Erasmus University Rotterdam

External person

Gema Requena

  • Agencia Espanola de Medicamentos y Productos Sanitarios

External person

Michael Hauptmann

  • Netherlands Cancer Institute
  • Department of Epidemiology and Biostatistics

External person

Jari Haukka

  • University of Helsinki

External person

Patrick Cyriel Souverein

  • Utrecht University

External person

Augustinus D G Krol

  • Leiden University Medical Center
  • Leiden University

External person

Yolanda Alvarez

  • European Medicines Agency
  • European Medicines Agency

External person

Annegien Broeks

  • Antoni Van Leeuwenhoek Hospital
  • Netherlands Cancer Institute
  • Division of Molecular Pathology

External person

Heleen K Bronsveld

  • Netherlands Cancer Institute
  • Utrecht University

External person

Rolf H H Groenwold

  • Utrecht University

External person

Xavier Kurz

  • European Medicines Agency (EMA)
  • European Medicines Agency

External person

Anssi Auvinen

  • Tampere University

External person

Diederick E Grobbee

  • Utrecht University
  • Cyprus University of Technology

External person

Gudrun Stefansdottir

  • Astellas Pharma Inc.

External person

A C G Egberts

  • Utrecht University

External person

Anna M van Eggermond

  • Netherlands Cancer Institute
  • Department of Epidemiology and Biostatistics

External person

Delphi G M Coppens

  • Utrecht University

External person

M Gil

  • Agencia Espanola de Medicamentos y Productos Sanitarios

External person

Anthony J Swerdlow

  • Cancer Prevention Institute of California
  • Institute of Cancer Research

External person

Josée M Zijlstra

  • VU University Medical Center

External person

Sofieke de Wilde

  • Leiden University

External person

Annemieke W.J. Opstal-van Winden

  • Netherlands Cancer Institute
  • Department of Epidemiology and Biostatistics

External person

Mirjam J Knol

  • National Institute of Public Health and the Environment

External person

Lamiae Grimaldi-Bensouda

  • Université de Versailles Saint-Quentin-en-Yvelines
  • LA-SER

External person

Hanno L Tan

  • University of Amsterdam
  • Academic Medical Centre

External person

Henk-Jan Guchelaar

  • Leiden University Medical Centre
  • Leiden University

External person

Rosie Cooke

  • Institute of Cancer Research

External person

Cécile P.M. Janus

  • Erasmus Medical Center Rotterdam
  • Erasmus University Rotterdam

External person

Miriam J Knol

  • Utrecht University
  • Institute for Pharmaceutical Sciences UU

External person

Ana Ruigomez

  • Fundación Centro Español de Investigación Farmacoepidemiológica

External person

Pauline Meij

  • Leiden University

External person

Luisa Ibáñez

  • Autonomous University of Barcelona

External person

Leslie L Robison

  • St. Jude Children Research Hospital

External person

Irene Klugkist

  • Utrecht University
  • University of Twente

External person

Christiane Gasse

  • Aarhus University
  • H. Lundbeck A/S
  • King's College London
  • University of Copenhagen
  • Aarhus University
  • Lundbeck Foundation Initiative for Integrative Psychiatric Research

External person

Ruth Brauer

  • Amgen Incorporated

External person

Gianmario Candore

  • European Medicines Agency
  • European Medicines Agency

External person

Nick Orr

  • Institute of Cancer Research

External person

Charlotte Rietbergen

  • Utrecht University

External person

A. De Boer

  • Utrecht University

External person

Stéphanie Tcherny-Lessenot

  • Global Pharmacovigilance and Epidemiology
  • Sanofi

External person

Sophia Zoungas

  • University of Sydney
  • Monash University

External person

Hugoline G de Haan

  • Department of Epidemiology and Biostatistics

External person

Marjanka K. Schmidt

  • Antoni Van Leeuwenhoek Hospital
  • Netherlands Cancer Institute
  • Department of Epidemiology and Biostatistics
  • Division of Molecular Pathology
  • University of Cologne

External person

Hendrika A. van den Ham

  • Utrecht University

External person

Jan A Kors

  • Boston University

External person

Frederieke H van der Baan

  • Department of Epidemiology and Biostatistics

External person

Louise C Strong

  • University of Texas MD Anderson Cancer Center

External person

Smita Bhatia

  • University of Alabama at Birmingham

External person

Roy G P J de Jong

  • VieCuri Medisch Centrum
  • Maastricht University
  • Utrecht University

External person

Gerdur Stefansdottir

  • Utrecht University
  • Institute for Pharmaceutical Sciences UU

External person

E. Martin

  • Agencia Espanola de Medicamentos y Productos Sanitarios
  • Diabetes Association of Trinidad and Tobago Trinidad

External person

Gerald Downey

  • Amgen Incorporated
  • University College Dublin
  • Teagasc - Irish Agriculture and Food Development Authority

External person

Hoda Anton-Culver

  • University of California at Irvine

External person

K Davis

  • GlaxoSmithKline

External person

Jean-Louis Durand

  • I'INRA
  • European Medicines Agency

External person

Andre P Kengne

  • University of Sydney

External person

Christopher A. Haiman

  • University of Southern California

External person

J J Campbell

  • Clinical Practice Research Datalink

External person

E. Ballarin

  • Fundació Institut Català de Farmacologia

External person

Joyce Sanders

  • Netherlands Cancer Institute

External person

Paul Dolin

  • Takeda Ltd.

External person

Maartje J Hooning

  • Erasmus MC Cancer Institute
  • Erasmus University Rotterdam

External person

A. Patel

  • University of Sydney

External person

Kwee Eng Ng

  • Clinical Practice Research Datalink

External person

J. Amelio

  • Amgen Incorporated

External person

M. Woodward

  • University of Sydney

External person

Juan R González

  • Agencia Espanola de Medicamentos y Productos Sanitarios

External person

M. Schoonen

  • Amgen Incorporated

External person

N. Boudiaf

  • GlaxoSmithKline

External person

John Logie

  • GlaxoSmithKline

External person

Douglas F. Easton

  • University of Cambridge
  • Centre for Cancer Genetic Epidemiology

External person

Baldomero Oliva

  • Pompeu Fabra University
  • Agencia Espanola de Medicamentos y Productos Sanitarios

External person

Jacobus A Burgers

  • Netherlands Cancer Institute

External person

M. Feudjo-Tepie

  • Amgen Incorporated

External person

Bas ter Braak

  • Leiden University

External person

Paul Baas

  • Netherlands Cancer Institute

External person

Fergus J Couch

  • Mayo Clinic Rochester, MN

External person

F. de Abajo Iglesias

  • Agencia Espanola de Medicamentos y Productos Sanitarios

External person

L van Dijk

  • Utrecht University

External person

Ad A M Masclee

  • Maastricht University

External person

Angela Cox

  • University of Sheffield
  • Sheffield University

External person

A Gallagher

  • Clinical Practice Research Datalink

External person

J. Pimenta

  • GlaxoSmithKline

External person

Julian Peto

  • London School of Hygiene and Tropical Medicine
  • London School of Hygiene & Tropical Medicine, London

External person

J. Hasford

  • Ludwig Maximilian University of Munich

External person

Paul Pharoah

  • University of Cambridge
  • Centre for Cancer Genetic Epidemiology

External person

Elinor J. Sawyer

  • Guy's and St Thomas' NHS Foundation Trust
  • King's College London

External person

Manel Sabaté

  • Fundació Institut Català de Farmacologia
  • University of Barcelona

External person

Michael Schaapveld

  • Netherlands Cancer Institute

External person

C. Huerta Alvarez

  • Agencia Espanola de Medicamentos y Productos Sanitarios

External person

Peter Vestergaard

  • Det Sundhedsvidenskabelige Fakultet
  • Klinisk Institut
  • Aalborg University Hospital
  • Hormon- og Stofskiftesygdomme (Endokrinologi)
  • Klinik Medicin

External person

Renate Udo

  • Utrecht University

External person

Pim N J Langendijk

  • University of Amsterdam

External person

O. Demol

  • Genzyme Corporation

External person

Svetlana V Belitser

  • Utrecht University

External person

J. Fortuny

  • Novartis

External person

Arthur A M Wilde

  • European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARD-Heart)
  • Academic Medical Centre
  • University of Amsterdam
  • European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart
  • European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart (ERN GUARDHEART)

External person

Lesley Wise

  • Takeda Ltd.

External person

E. Rivero

  • Novartis

External person

Manuel Lopez-Ibanez

  • Fundació Institut Català de Farmacologia

External person

Karin E Smedby

  • Karolinska Institutet

External person

Elisa Martin

  • Spanish Agency for Medicines and Medical Devices (AEMPS)

External person

Sara E. Dobbins

  • Institute of Cancer Research

External person

E. N. Van Roon

  • MCL North Hospital

External person

Victor Enciso-Mora

  • Institute of Cancer Research

External person

Luis A. García Rodríguez

  • Centro Español de Investigación Farmacoepidemiólogica (CEIFE), Madrid

External person

A. Malcolm R. Taylor

  • University of Manchester
  • University of Birmingham

External person

Annegien Broeks

  • Antoni Van Leeuwenhoek Hospital

External person

Yolande C. Keulemans

  • Zuyderland Medical Centre

External person

Richard S Houlston

  • Institute of Cancer Research
  • Mayo Clinic Rochester, MN

External person

Patrick H Ryan

  • Columbia University
  • Johnson & Johnson

External person

J. A. Chalmers

  • De Nationale Geologiske Undersøgelser for Danmark og Grønland

External person

Bengt Glimelius

  • Karolinska University Hospital + Akademiska sjukhuset, Uppsala University
  • Karolinska Institutet
  • Uppsala University

External person

Lodewyk F A Wessels

  • Netherlands Cancer Institute
  • Delft University of Technology

External person

Ronald Van Eijk

  • Leiden University

External person

Bruno H Ch Stricker

  • Erasmus University Rotterdam
  • Boston University

External person

Nancy Ann Dreyer

  • QuintilesIMS

External person

Stephen Hamilton-Dutoit

  • Aarhus University

External person

Ruth F Jarrett

  • University of Glasgow

External person

Ana S Maciel Afonso

  • Utrecht University

External person

Helga Westers

  • University of Groningen

External person

J. R. Laporte

  • Fundació Institut Català de Farmacologia

External person

Ellen T. Chang

  • Cancer Prevention Institute of California
  • Stanford University

External person

J A Chalmers

  • GEUS (emer.)
  • University of Sydney

External person

Richard W.M. van der Maazen

  • Radboud University Medical Centre Nijmegen

External person

Jelle Wesseling

  • Netherlands Cancer Institute

External person

E. Voogd

  • Utrecht University

External person

Marieke Tabo Blom

  • Academic Medical Centre

External person

Michael N. Moore

  • Plymouth Marine Laboratory

External person

Eve Roman

  • University of York

External person

Douglas F Easton

  • University of Cambridge

External person

J. C. Korevaar

  • Netherlands Institute for Health Services Research

External person

U. Hesse

  • Sundhedsstyrelsen

External person

Ilja M Nolte

  • University of Groningen

External person

Karen R. Kooijman

  • Netherlands Cancer Institute

External person

Domir De Bakker

  • Utrecht University

External person

Torbjörn Callréus

  • University of Copenhagen

External person

Lesley Shield

  • University of Glasgow

External person

Peter Vestergaard

  • Medicinsk Endokrinologisk Afdeling, Aalborg Sygehus

External person

Anke-Hilse Maitland-van der Zee

  • Utrecht University
  • University of Amsterdam

External person

P F Rønn

  • Sundhedsstyrelsen

External person

Annette Lake

  • University of Glasgow

External person

Arjan Diepstra

  • Lund University

External person

Daniel G. M. Molin

  • Uppsala University

External person

Peter Broderick

  • Institute of Cancer Research

External person

Marnix L. Lybeert

  • Catharina Hospital

External person

Angela Cox

  • University of Sheffield

External person

Anke Van Den Berg

  • University of Groningen

External person

Asta Försti

  • German Cancer Research Center
  • Lund University

External person

Tracy Lightfoot

  • University of York

External person

Mikael Thomsen

  • Conrig Pharma A/S

External person

Joe Dennis

  • University of Cambridge

External person

Paul Pharoah

  • University of Cambridge

External person

Sukhwinder Jossan

  • Ferring Pharmaceuticals A/S (Biz)
  • Ferring Pharmaceuticals

External person

Ingrid Hofland

  • Netherlands Cancer Institute

External person

Nielka P. van Erp

  • Radboud University Nijmegen

External person

Robert Hofstra

  • University of Groningen

External person

Andreas Engert

  • University of Cologne

External person

Kathryn Starzyk

  • QuintilesIMS

External person

Lotte Huinink

  • Erasmus University Rotterdam

External person

Ibrahima Diallo

  • Université Paris-Sud

External person

Inge M. Krul

  • Netherlands Cancer Institute

External person

Johanna H M Driessen

  • Maastricht University
  • Utrecht University

External person

Pernille Vahl

  • Aarhus University Hospital /Aarhus Universitetshospital
  • Aarhus University

External person

Florent de Vathaire

  • Université Paris-Sud

External person

W. Pestman

  • Utrecht University
  • KU Leuven

External person

Ausrele Kesminiene

  • International Agency for Research on Cancer

External person

Peter Devilee

  • Leiden University
  • Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, Ontario, Canada; Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario

External person

Franciska de Vries

  • Lancaster University
  • Utrecht University

External person

Amy Lloyd

  • Institute of Cancer Research

External person

Pirn Langendijk

  • University of Amsterdam

External person

Elke Pogge Von Strandmann

  • University of Cologne

External person

Cornelis B Lambalk

  • Vrije Universiteit Amsterdam

External person

Lotte M. Knapen

  • Maastricht University

External person

Joe Dennis

  • University of Cambridge

External person

K. C B Roes

  • Utrecht University

External person

Tom Van Wezel

  • Leiden University

External person

Kari Hemminki

  • German Cancer Research Center
  • Lund University

External person

Alan Ashworth

  • Institute of Cancer Research

External person

Bianca Olver

  • Institute of Cancer Research

External person

S Ali

  • Utrecht University

External person

Christopher A Haiman

  • University of Southern California

External person

Arthur A Wilde

  • University of Amsterdam

External person

Pierre Engel

  • QuintilesIMS

External person

Henrik Hjalgrim

  • Statens Serum Institut

External person

Hoda Anton-Culver

  • University of California at Irvine

External person

Jayaram Vijayakrishnan

  • Institute of Cancer Research

External person

Sten Cornelissen

  • Netherlands Cancer Institute
  • Antoni Van Leeuwenhoek Hospital

External person

Dorothy Montgomery

  • University of Glasgow

External person

Hans-Olov Adami

  • Karolinska Institutet
  • Harvard University
  • Harvard School of Public Health
  • University of Oslo

External person

Stella Blackburn

  • QuintilesIMS

External person

Jaap W Deckers

  • Erasmus Medical Center Rotterdam

External person

Hans Hoogland

  • LEO Pharma AS

External person

Yussanne Ma

  • Institute of Cancer Research
  • University of British Columbia

External person

Floor Van Leeuwen

  • Netherlands Cancer Institute

External person

Alison M. Gallagher

  • Ulster University

External person

Katrin S. Reiners

  • University of Cologne

External person

Sandra Fase

  • Netherlands Cancer Institute

External person

Pilar Ferrer-Escorihuela

  • European Synchrotron Radiation Facility
  • Fundació Institut Català de Farmacologia

External person

Julian Peto

  • London School of Hygiene and Tropical Medicine

External person

Daan J A Crommelin

  • Utrecht University

External person

Sander Croes

  • Maastricht University

External person

Rudolph Willem Koster

  • Academic Medical Centre

External person